News | July 16, 2025
Waters, BD biosciences unit agree to $17.5 billion merger
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Celecoxib is a nonsteroidal anti-inflammatory drug
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations
Subscribe To Our Newsletter & Stay Updated
